Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

SARS-CoV-2 present significantly longer in stool than in respiratory, serum samples

Publish date:: April 27, 2020

Key clinical point: Viral clearance should be monitored on the basis of disease severity for COVID-19 patients and stool must be considered as a longer risk for infection.

Major finding: The median duration of virus in the respiratory samples of patients with severe disease (21 days) was significantly longer than in patients with mild disease (14 days; P = .04)

Study details: A retrospective, single-center study of 96 COVID-19 patients; 22 with mild disease and 74 with severe disease.

Disclosures: The study was funded by the China National Mega-Projects for Infectious Diseases and the National Natural Science Foundation of China. The authors reported they had no disclosures.

Citation:

Zheng S et al. BMJ. 2020;369:m1443.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Annual WCC visits significantly limit asthma worsening,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Microplastics permeate human placentas,

Must Reads in COVID-19 Updates

Anorexia and diarrhea top list of GI symptoms in COVID-19 patients,

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Upper GI bleeds in COVID-19 not related to increased mortality,

Obesity, hypoxia predict severity in children with COVID-19,